MTNB

SEC source: 0000905718-22-000007 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,472

F1 · shares: On December 31, 2021, the Reporting Person was issued 7,859 shares of common stock, par value $0.0001 per share, pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-21-001603 · matinasbio_fm4dec142021.xml · derivative · entry 1

Hoover Thomas · CIK 0001898716 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 850,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001609 · matinas_fm4dec152021.xml · derivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001613 · matinas_fm4dec142021.xml · derivative · entry 1

Kucinski Keith A · CIK 0001763405 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001615 · matinas_fm4dec142021.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,658,100

Underlying: Common Stock · 1,658,100 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001611 · matinas_fm4dec142021.xml · derivative · entry 1

Hui Liu · CIK 0001834660 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001607 · matinas_fm4dec142021.xml · derivative · entry 1

Matkovits Theresa · CIK 0001745393 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-001605 · matinas_fm4dec142021.xml · derivative · entry 1

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,600

Underlying: Common Stock · 587,600 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0001493152-21-026987 · ownership.xml · derivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,882

Underlying: Common Stock · 90,882 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-026991 · ownership.xml · derivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,882

Underlying: Common Stock · 90,882 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-026989 · ownership.xml · derivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,882

Underlying: Common Stock · 90,882 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-026993 · ownership.xml · derivative · entry 1

Giordano Natasha · CIK 0001315585 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,882

Underlying: Common Stock · 90,882 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-026990 · ownership.xml · derivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,882

Underlying: Common Stock · 90,882 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-026985 · ownership.xml · derivative · entry 1

Corzo Kathryn Penkus · CIK 0001884123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,763

Underlying: Common Stock · 181,763 shares

Expires 2031-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on November 30, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-21-024397 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,613

F1 · shares: On September 30, 2021, the Reporting Person was issued 6,106 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-21-022716 · ownership.xml · nonDerivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,919,715

F1 · kind: Shares received pursuant to an amendment to the Agreement and Plan of Merger dated as of January 29, 2015 by an among the Issuer, Saffron Merger Sub, Inc. and Aquarius Biotechnologies Inc.

SEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 2

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 3,336,444

SEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001493152-21-016565 · ownership.xml · nonDerivative · entry 2

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 2,841,822

SEC source: 0001493152-21-016565 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT)

Disclosed balance after: 1,358,122

SEC source: 0001493152-21-015878 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,507

F1 · shares: On June 30, 2021, the Reporting Person was issued 10,244 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-21-000832 · matinasbio_fm4jun192021.xml · derivative · entry 3

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000832 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000832 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,092

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · derivative · entry 3

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,457,565

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,437,565

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · derivative · entry 3

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,263

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · derivative · entry 5

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 1,560,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 1,360,905

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0000905718-21-000828 · matinasbio_fm4jun192021.xml · derivative · entry 3

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000828 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 649,958

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000828 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,958

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · derivative · entry 3

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 840,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,011

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 4

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 1,320,905

SEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 3

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert Conrad 2019 Grantor Retained Annuity Trust (GRAT)

Disclosed balance after: 0

SEC source: 0000905718-21-000556 · wikler_fm4mar312021.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,863

F1 · shares: On March 31, 2021, the Reporting Person was issued 7,560 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-21-012764 · ownership.xml · derivative · entry 7

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 100

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

SEC source: 0001493152-21-012764 · ownership.xml · derivative · entry 6

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

SEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 2

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 175,000

SEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,622

SEC source: 0001493152-21-000135 · ownership.xml · derivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-12-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.

SEC source: 0001493152-21-000136 · ownership.xml · derivative · entry 1

Matkovits Theresa · CIK 0001745393 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 425,000 shares

Expires 2030-12-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.

SEC source: 0001493152-21-000134 · ownership.xml · derivative · entry 1

Hui Liu · CIK 0001834660 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2030-12-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.

SEC source: 0001493152-21-000133 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires 2030-12-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.